Vaccitech Q2 net loss $23.8M ($0.62 per share); cash $173M extends runway into Q2 2025

Barinthus Biotherapeutics plc.

2023-Q2 EPS reported -$1.10 revenue$802,000

Net loss $23.8M, widened from $18.2M in Q1 2023; revenue $0.3M from AstraZeneca royalties.
R&D expense $13.5M, up from $9.8M Q1, driven by HBV and SNAPvax IND-enabling studies.
Cash $173M vs $191.3M at Q1; operating cash burn $17M; expects runway into Q2 2025.
Final HBV002 data presented at EASL; VTP-300 induced HBsAg reductions; interim Phase 2 data expected H2 2023.
CMO Dr. Margaret Marshall retired July 2023; will remain as consultant.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Barinthus Biotherapeutics plc. reported second quarter of 2023 results: revenue $0.3 million.

Period: second quarter of 2023
Revenue: $0.3 million
Result: reported results

Exact text from the filing

plans, we expect our cash runway to fund our operating expenses and capital expenditure requirements into the second quarter of 2025. 2 · Revenue: Revenue consisted of $0.3 million in the second quarter of 2023 compared to $0.5 million in the first quarter of 2023. Revenue was comprised of the Company’s share of royalties received by Oxford University

View on SEC.gov

Browse all earnings releases →

Barinthus Biotherapeutics plc. filing history →

Source: SEC EDGAR

accession 0001104659-23-089578

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.